Applied Therapeutics Inc. - 10-K filing on 2022-03-10

SUBSEQUENT EVENTS	12 Months Ended
Dec. 31, 2021
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	15. SUBSEQUENT EVENTS Cowen Equity Distribution Agreement On January 26, 2022, the Company entered into an equity distribution agreement (the “Cowen Equity Distribution Agreement) with Cowen and Company, LLC (“Cowen”), as a sales agent, to sell shares of the Company’s common stock, from time to time, having an aggregate offering price of up to $100.0 million. Pursuant to the Cowen Equity Distribution Agreement shares of our common stock may be offered and sold through the sales agent in sales deemed “at-the-market” offerings under the Securities Act of 1933, as amended, or the Securities Act. Under the Cowen Equity Distribution Agreement, the sales agent will be entitled to compensation of up to 3% of the gross offering proceeds of all shares of our common stock sold through it pursuant to the Cowen Equity Distribution Agreement. In connection with the sale of shares of our common stock on our behalf, the sales agent may be deemed to be “underwriters” within the meaning of the Securities Act, and the compensation paid to the sales agent may be deemed to be underwriting commissions or discounts. Extension of the 2020 Miami Sponsored Research Agreement On February 15, 2022 and effective January 1, 2022, the Company entered into an amendment to the 2020 Miami Research Agreement, under which the University of Miami will extend the research study relating to SORD neuropathy and deliver a final report on the study to the Company. The term of the research agreement is from January 1, 2022 through May 31, 2022. The consideration for the amendment to the 2020 Miami Research Agreement is $0.3 million.

SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2021

15. SUBSEQUENT EVENTS

Cowen Equity Distribution Agreement

On January 26, 2022, the Company entered into an equity distribution agreement (the “Cowen Equity Distribution Agreement) with Cowen and Company, LLC (“Cowen”), as a sales agent, to sell shares of the Company’s common stock, from time to time, having an aggregate offering price of up to $100.0 million. Pursuant to the Cowen Equity Distribution Agreement shares of our common stock may be offered and sold through the sales agent in sales deemed “at-the-market” offerings under the Securities Act of 1933, as amended, or the Securities Act. Under the Cowen Equity Distribution Agreement, the sales agent will be entitled to compensation of up to 3% of the gross offering proceeds of all shares of our common stock sold through it pursuant to the Cowen Equity Distribution Agreement. In connection with the sale of shares of our common stock on our behalf, the sales agent may be deemed to be “underwriters” within the meaning of the Securities Act, and the compensation paid to the sales agent may be deemed to be underwriting commissions or discounts.

Extension of the 2020 Miami Sponsored Research Agreement

On February 15, 2022 and effective January 1, 2022, the Company entered into an amendment to the 2020 Miami Research Agreement, under which the University of Miami will extend the research study relating to SORD neuropathy and deliver a final report on the study to the Company. The term of the research agreement is from January 1, 2022 through May 31, 2022. The consideration for the amendment to the 2020 Miami Research Agreement is $0.3 million.